Consensus LivaNova PLC

Stocks

LIVN

GB00BYMT0J19

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq 00:00:00 31/10/2026 +04			5-day change	1st Jan Change
78.97 ^USD	-2.81%		-2.83%	+28.34%

10-23	LivaNova PLC Announces Full 36-Month Core-VNS Results Demonstrating Sustained and Increasing Benefits of VNS Therapy for Drug-Resistant Epilepsy	CI
09-15	Livanova Insider Sold Shares Worth $273,032, According to a Recent SEC Filing	MT

Evolution of the Average Target: LivaNova PLC

Evolution of the Target Price: LivaNova PLC

Changes in Analyst Recommendations: LivaNova PLC

6522e.xNc5ZCXtcRH83t-x8R7Hes_bi72PGkH1u3_rQErq8fs.vr5_FnSUAlSdqajWp1HwO4LpudC8awCRjgqeOS6OvpSzmAwGabgLRYanrA~3328a6d5f25131948180bbf822d0981d

Analysts' recommendations: LivaNova PLC

02-25	Needham Adjusts Price Target on LivaNova to $81 From $64	MT
12-19	KeyBanc Initiates LivaNova at Overweight With $81 Price Target	MT
01/10/25	LivaNova Shares Fall After Goldman Sachs Downgrade	MT
01/10/25	Goldman Sachs Downgrades LivaNova to Neutral From Buy, Trims Price Target to $55 From $56	MT
06/08/25	LivaNova beats estimates for Q2 revenue, raises FY guidance	RE
20/05/25	Wolfe Upgrades LivaNova to Outperform From Peer Perform, Price Target is $60	MT
26/02/25	Wolfe Research Downgrades LivaNova to Peer Perform From Outperform	MT
17/09/24	Baird Upgrades LivaNova to Outperform From Neutral	MT
31/07/24	Needham Raises LivaNova's Price Target to $75 From $72, Buy Rating Maintained	MT
27/02/24	Barclays Adjusts Price Target on LivaNova to $61 From $57, Keeps Equalweight Rating	MT
26/02/24	Barclays Raises Price Target on LivaNova to $61 From $57, Maintains Equalweight Rating	MT
22/02/24	Baird Adjusts LivaNova's Price Target to $62 From $56, Keeps Neutral Rating	MT
22/02/24	Wolfe Research Adjusts LivaNova's Price Target to $65 From $58, Keeps Outperform Rating	MT
22/02/24	Mizuho Securities Adjusts Price Target on LivaNova to $75 From $70, Maintains Buy Rating	MT
21/02/24	Needham Adjusts Price Target on LivaNova to $72 From $62, Keeps Buy Rating	MT
20/02/24	Mizuho Securities Upgrades LivaNova to Buy From Neutral, Raises Price Target to $70 From $60	MT
23/10/23	Needham Adjusts LivaNova Price Target to $62 From $71, Maintains Buy Rating	MT
06/09/23	HSBC Initiates LivaNova With Hold Rating, Price Target is $52	MT
08/05/23	Barclays Adjusts Price Target on LivaNova to $51 From $45, Maintains Equalweight Rating	MT
03/05/23	Needham Adjusts LivaNova's Price Target to $63 From $77, Keeps Buy Rating	MT
14/04/23	Mizuho Initiates LivaNova at Neutral With $48 Price Target	MT
21/12/22	Barclays Initiates Coverage on LivaNova With Equal Weight Rating, $62 Price Target	MT
23/11/22	Goldman Sachs Adjusts LivaNova's Price Target to $63 From $73, Keeps Buy Rating	MT
03/11/22	Needham Adjusts Price Target on LivaNova to $77 From $88, Maintains Buy Rating	MT
16/08/22	Goldman Sachs Cuts Price Target on LivaNova to $73 From $85, Maintains Buy Rating	MT

More recommendations

Other Medical Equipment, Supplies & Distribution

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	LIVANOVA PLC					+11.44%
	ABBOTT LABORATORIES					+13.34%
	STRYKER CORPORATION					+16.32%
	MEDTRONIC PLC					+7.73%
	ESSILORLUXOTTICA					+21.16%
	CENCORA, INC.					+11.66%
	HOYA CORPORATION					+16.36%
	BECTON, DICKINSON AND COMPANY					-1.4%
	IDEXX LABORATORIES, INC.					+20.56%
	ALCON INC.					+26.66%
	Average					+14.39%
	Weighted average by Cap.					+13.92%